Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer

@article{Saif2016Phase1S,
  title={Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer},
  author={Muhammad Wasif Saif and James A. Knost and Elena Gabriela Chiorean and Siva Rama Prasad Kambhampati and Danni Yu and Bronislaw Pytowski and Amy Qin and John Sae Wook Kauh and Bert H. O’Neil},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2016},
  volume={78},
  pages={815-824}
}
Metastasis of solid tumors to regional lymph nodes is facilitated by tumor lymphangiogenesis, which is primarily mediated by the vascular endothelial growth factor receptor 3 (VEGFR-3). We conducted a phase 1 dose-escalation (part A) study of the VEGFR-3 human immunoglobulin G subclass 1 monoclonal antibody LY3022856 in advanced solid tumors, followed by a colorectal cancer (CRC) expansion (part B). Part A evaluated the safety profile and maximum tolerated dose (MTD) of LY3022856 in patients… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
5 Extracted Citations
43 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 43 references

: a review of the current knowledge

  • SF Schoppmann, B Jesch, J Zacherl, MF Riegler, J Friedrich, P Birner
  • 2013

Similar Papers

Loading similar papers…